Skip to main content
Clinical Trials/NCT02904967
NCT02904967
Completed
Not Applicable

Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome

Assistance Publique Hopitaux De Marseille1 site in 1 country221 target enrollmentJanuary 18, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Venous Thromboembolism
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
221
Locations
1
Primary Endpoint
allelic frequency of 500,000 already genotyped polymorphisms
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years.

Reduce the risk of recurrence is a serious public health issue. For this it is necessary to identify patients at high risk of recurrence. However, until now, only 50% of recurrences are in the presence of known risk factors, suggesting that there are still yet unidentified risk factors.

The assumption behind this project is that there are specifically associated genetic polymorphisms to the risk of VTE recurrence.

The aim of our project is to identify these polymorphisms from genome-wide data MARTHA cohort. This cohort is composed of 1542 subjects from the Marseille region with at least one episode of VTE documented. Patients in the cohort MARTHA have all been genotyped for approximately 500,000 polymorphisms.

The investigators want to achieve a case-control study nested in the cohort MARTHA. Subjects with recurrent VTE (the case) will be compared to subjects with only one episode of VTE (the controls). The allelic frequencies of polymorphisms previously genotyped 500,000 will be compared between cases and controls. The identification of these new genetic variants associated with VTE recurrence should allow us to improve the pathophysiological knowledge of the disease, reduce the frequency of episodes and focus research on new therapeutic approaches.

Registry
clinicaltrials.gov
Start Date
January 18, 2013
End Date
August 9, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Caucasian topic
  • Personal history of VTE confirmed by the reference diagnostic tests

Exclusion Criteria

  • Pregnant or breastfeeding women

Outcomes

Primary Outcomes

allelic frequency of 500,000 already genotyped polymorphisms

Time Frame: 36 months

Study Sites (1)

Loading locations...

Similar Trials